NETANYA, Israel, March 18, 2019 /PRNewswire/ -- Theranica, a bio-medical technology company developing advanced electroceuticals for migraine and other prevalent diseases, announced the closing of its round B of financing, of $35 Million, led by aMoon, Israel's largest healthcare VC. All existing investors of the company – Lightspeed Venture Partners, LionBird, Corundum Open Innovation and Takoa – participated in the round. Nerivio Migra®, the company's novel remote neuromodulation device for acute treatment of migraine, is currently under review of the FDA.